| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,383,000 |
| Market
Cap: |
1.44(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.53 - $27.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 2 |
| Insider 3/6 Months : 2.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
53 |
53 |
53 |
| Total Buy Value |
$0 |
$1,013 |
$1,013 |
$1,013 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
10,465 |
151,096 |
184,593 |
219,438 |
| Total Sell Value |
$246,302 |
$3,206,005 |
$4,083,291 |
$5,152,397 |
| Total People Sold |
5 |
6 |
6 |
7 |
| Total Sell Transactions |
5 |
12 |
13 |
28 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Saran Atul |
Director |
– • – |
2013-12-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,319,522 |
1,319,522 |
|
- |
|
| Stafford John S Jr |
10% Owner |
– – • |
2013-12-06 |
4 |
B |
$5.50 |
$1,512,500 |
D/D |
275,000 |
2,000,443 |
2.45 |
- |
|
| Stafford John S Jr |
10% Owner |
– – • |
2013-12-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,725,353 |
1,725,443 |
|
- |
|
| Fleming Jonathan |
Director |
– • – |
2013-12-06 |
4 |
A |
$0.00 |
$0 |
I/I |
790,881 |
790,881 |
|
- |
|
| Desjarlais John R |
Vice President, ResearchOffice |
• – – |
2013-12-02 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
19 |
|
- |
|
| Kuch John J |
Vice President, FinanceOfficer |
• – – |
2013-12-02 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
103 |
|
- |
|
| Stafford John S Jr |
10% Owner |
– – • |
2013-12-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
90 |
|
- |
|
| Stafford John S Iii |
Director |
– • • |
2013-12-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,858 |
|
- |
|
| Dahiyat Bassil I |
President and CEOOfficer |
• • – |
2013-12-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,156 |
|
- |
|
334 Records found
|
|
Page 14 of 14 |
|
|
0.17 (0.78%) 
